Tag Archive for: ADCs

Adcendo Announces US FDA Clearance of IND Application for Phase I/II First-in-Human ADCElerate-01 Trial of ADCE-D01 (uPARAP Receptor Targeting ADC) Trial in Patients with Metastatic and/or Unresectable Soft Tissue Sarcoma (STS)

/in

ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor which is highly overexpressed in mesenchymal cancers including multiple STS subtypes The Phase I/II ADCElerate-01 trial is designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of ADCE-D01 as a monotherapy in patients with metastatic and/or unresectable STS Copenhagen, Denmark, October 8th, 2024 – […]

Read more

Heidelberg Pharma: New Clinical Data on Lead ADC Candidate HDP-101 Presented at IMS 2024 Demonstrating Complete Remission in One Patient

/in

Data from the study with the lead ADC candidate, HDP-101, show elimination of tumor cells in one patient Clinical data from IMS will be presented in R&D webinar on 15 October at 17:00 CEST / 11:00 EDT Ladenburg, Germany, 1 October 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today […]

Read more

Novo Holdings co-leads £90 million ($114 million) Series A financing for Myricx Bio to advance a novel payload class for antibody-drug conjugates

/in

Funds will be used to build out Myricx Bio’s proprietary payload platform and advance its pipeline through clinical proof of concept Novo Holdings Venture Investments Partner Michael Bauer will join Myricx Board of Directors and Principal Max Klement will join Myricx Board as an Observer This is the largest European biotech Series A financing this […]

Read more

Adcendo ApS Announces Extension of Series A Financing to EUR 98M to Further Bolster its First-in-Class ADC Pipeline

/in

Raises additional 16M EUR led by Dawn Biopharma, a platform controlled by KKR, with participation from existing investors Funds will be used to further strengthen growing pipeline of first in class ADC assets, including lead asset targeting uPARAP  Iyona Rajkomar, Managing Partner at Dawn Biopharma, joins Adcendo Board of Directors Copenhagen, Denmark, May 29th, 2024 – […]

Read more

Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024

/in

Ladenburg, Germany, 23 May 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that its management team will be participating and presenting on its proprietary ADC technology platforms at the following scientific conferences in May and June in 2024. Read more…

Read more